Babic, Ana
Cramer, Daniel W.
Kelemen, Linda E.
Köbel, Martin
Steed, Helen
Webb, Penelope M.
Johnatty, Sharon E.
deFazio, Anna
Lambrechts, Diether
Goodman, Marc T.
Heitz, Florian
Matsuo, Keitaro
Hosono, Satoyo
Karlan, Beth Y.
Jensen, Allan
Kjær, Susanne K.
Goode, Ellen L.
Pejovic, Tanja
Moffitt, Melissa
Høgdall, Estrid
Høgdall, Claus
McNeish, Iain
Terry, Kathryn L.
Funding for this research was provided by:
Canadian Institutes of Health Research (MOP-86727)
Medical Research and Materiel Command (DAMD17-01-1-0729)
National Health and Medical Research Council (199600, 400281)
Cancer Councils of New South Wales, Victoria, Queensland, South Australia and Tasmania, Cancer Foundation of Western Australia (Multi-state application numbers 191, 211, and 182)
Nationaal Kanderplan
National Institutes of Health (R01-CA58598, N01-CN-55424 and N01-PC-67001, R01-CA61107, R01-CA54419, P50-CA136393, P30-CA15083)
National Cancer Institute (R01-CA193965)
Grant-in-Aid for the Third Term Comprehensive 10-Year Strategy for Cancer Control from the Ministry of Health, Labour and Welfare
American Cancer Society (SIOP-06-258-01-COUN)
National Center for Advancing Translational Sciences (UL1TR000124)
Danish Cancer Society (94 222 52)
Danish Mermaid I project
Mayo Foundation
Minnesota Ovarian Cancer Alliance
Fred C. and Katherine B. Andersen Foundation
Sherie Hildreth Ovarian Cancer Foundation
Herlev Hospitals Forskningsråd, Direktør Jacob Madsens og Hustru Olga Madsens fond, Arvid Nilssons fond, Gangsted fonden, Herlev Hospitals Forskningsråd
Cancer Research UK (C536/A13086, C536/A6689)
Imperial Experimental Cancer Research (C1312/A15589)
Article History
Received: 16 October 2016
Accepted: 19 December 2016
First Online: 3 January 2017